Provenge Immunotherapy for Prostate Cancer - Allan J. Pantuck, MD - UCLAMDChat

Overview

Explore the innovative use of Provenge immunotherapy in treating advanced prostate cancer in this informative 25-minute video lecture by Dr. Allan J. Pantuck, professor at UCLA Department of Urology. Gain insights into the background and rationale behind immune-based cancer therapies, focusing on Provenge's FDA-approved treatment that utilizes genetically engineered immune cells. Delve into the indications, benefits, and potential side effects of this groundbreaking therapy. Learn about the concept of immune surveillance, the advantages of immunotherapy, and its recognition as a breakthrough in cancer treatment. Understand the treatment window, patient selection criteria, and effectiveness of Provenge, including its impact on PSA levels. Discover the day-of-infusion process, self-limited course of treatment, and other emerging immunotherapies in the field of prostate cancer management.

Syllabus

Introduction
Cancer
Prostate Cancer
Treatment
What is Provenge
What is autologous
Features of cancer
Immune surveillance
What is immunotherapy
Origins of immunotherapy
Advantages of immunotherapy
Breakthrough of the year
Immunotherapy
FDA Approved Immunotherapies
What is a Therapeutic Vaccine
Treatment Window
Why Provenge
Side Effects
Day of the Infusion
Self Limited Course
Summary
Who is most likely to benefit
What is PSA
Effectiveness
Other immunotherapies